Printer Friendly

GENSIA AND ARAMED RECEIVE RIGHTS TO DEVELOP ORAL ARA COMPOUND FOR CARDIOVASCULAR DISEASE

 SAN DIEGO, Sept. 13 /PRNewswire/ -- Gensia Inc. (NASDAQ: GNSA) and Aramed Inc. (NASDAQ: ARAMZ) announced today that Gensia and Aramed plan to develop compound GP-1-531, an adenosine regulating agent (ARA), for use in cardiovascular disease. This compound had been previously presented to Marion Merrell Dow Inc. (MMDI) for evaluation under the terms of the Technology Option and License Agreement formed between Gensia and MMDI in 1990. MMDI has decided not to exercise its option to license the compound. GP-1-531 was the second compound presented to MMDI under the Agreement. MMDI licensed the first of these compounds GP-1-468-3, in August 1992, which is scheduled to begin Phase 1 clinical trials in the first half of 1994.
 Aramed is a special purpose corporation formed by Gensia and has the rights to develop the intravenous forms of ARA compounds for cardiovascular and cerebrovascular disease as well as intravenous and oral forms of ARAs for epilepsy and acute seizures. In addition, Aramed has the right to develop in North America and Europe the intravenous form of an ARA compound that MMDI elects not to license under its Agreement with Gensia. Under the terms of the Aramed agreement with Gensia, Gensia will be responsible for development of the intravenous form of GP-1-531 for Aramed for use in the treatment of acute cardiovascular disease. In addition Gensia has the rights to develop the orally active forms of GP-1-531 and plans to proceed with the development of this compound for chronic cardiovascular disease.
 "We are very excited about having the rights back to develop the oral applications of GP-1-531 at Gensia and the intravenous forms with Aramed. This is another exciting ARA compound, which is potentially available in both oral and intravenous forms, for the treatment of cardiovascular disease," said David F. Hale, chairman, president and chief executive officer of Gensia Inc. "We continue to believe that ARAs are an important new class of drugs with significant potential in cardiovascular disease."
 Gensia is a San Diego-based biopharmaceutical company formed to discover, develop, manufacture and market novel pharmaceutical products for the treatment and diagnosis of human diseases. Aramed is a special purpose corporation, formed to accelerate the discovery, research and development of certain compounds utilizing Gensia's ARA technology. Aramed has contracted with Gensia to conduct research and development in three program areas: second generation ARAs for use in the intravenous treatment of acute cardiovascular disorders, ARAs for the oral and intravenous treatment of certain seizure disorders, and ARAs and adenosine agonists for the intravenous treatment of acute cerebrovascular disorders.
 -0- 9/13/93
 /CONTACT: Elizabeth A. Gard, Gensia, 619-546-8300/
 (GNSA ARAMZ)


CO: Gensia Inc.; Aramed Inc. ST: California IN: MTC SU:

JL-LM -- SD003 -- 1135 09/13/93 09:03 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 13, 1993
Words:452
Previous Article:CHILTON POLL: TWENTYSOMETHINGS EAGER TO TRAVEL THE INFORMATION HIGHWAY WITH INTERACTIVE TV
Next Article:CF MOTORFREIGHT NAMED PRIMARY CARRIER FOR U S WEST
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters